Idera Pharmaceuticals Inc (IDRA)

2.23
NASDAQ : Health Care
Prev Close 2.26
Day Low/High 2.20 / 2.28
52 Wk Low/High 1.30 / 3.33
Avg Volume 944.80K
Exchange NASDAQ
Shares Outstanding 149.63M
Market Cap 338.17M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Idera Pharmaceuticals Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-tumor Responses Associated With Tumor-Specific Memory

Idera Pharmaceuticals Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-tumor Responses Associated With Tumor-Specific Memory

Clinical Data from Ongoing Phase 1/2 Trial of IMO-2125 in anti-PD-1 Refractory Melanoma to be presented Sunday, September 10 at the European Society for Medical Oncology Congress (ESMO) in Madrid, Spain

Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Corporate Update

Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Corporate Update

IMO-2125 Clinical Trial Data Update at ESMO in September

Idera Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides Corporate Update

IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma

Short Interest Makes 13.7% Move For IDRA

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 1,597,524 share increase in total short interest for Idera Pharmaceuticals Inc , to 13,276,826, an increase of 13.68% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Idera Pharmaceuticals Announces Organizational Update

Antisense Pioneer and Idera Founder Dr. Sudhir Agrawal Set to Retire

Idera Pharmaceuticals Advances Investigational Treatment - Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma

All objectives successfully met in Phase 1 portion of combination trial and the company is now enrolling the Phase 2 trial

Idera Pharmaceuticals Presents Clinical Translational And Pre-Clinical Data From IMO-2125 Development Program At The American Association For Cancer Research (AACR) 2017 Annual Meeting

- Clinical Translational Data of Immune Parameters Generated Demonstrate IMO-2125 Mechanism of Action Correlated with Previously Reported Clinical Results -

Commit To Buy Idera Pharmaceuticals At $2, Earn 62.9% Annualized Using Options

Investors considering a purchase of Idera Pharmaceuticals Inc stock, but tentative about paying the going market price of $2.29/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May put at the $2 strike, which has a bid at the time of this writing of 20 cents.

Idera Pharmaceuticals Presents Update From Ongoing Phase 1 Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Results Demonstrate IMO-2125 plus ipilimumab combination is tolerable at all dose levels studied and has demonstrated durable clinical activity in PD-1 Refractory Melanoma

Short Interest Decreases By 23% For IDRA

Short Interest Decreases By 23% For IDRA

The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 2,502,803 share decrease in total short interest for Idera Pharmaceuticals Inc , to 8,361,439, a decrease of 23.04% since 12/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Idera Pharmaceuticals And Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement For The Worldwide Rights To IMO-9200

Idera Pharmaceuticals And Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement For The Worldwide Rights To IMO-9200

Idera receives $15 million upfront, with potential IMO-9200-related milestone payments totaling up to $140 million plus royalties

Tax-Loss Selling Offers Stock-Picking Opportunities

Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies are scooping up shares of their own stock lately.

TheStreet Quant Rating: D (Sell)